Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.52 |
| ▸ | JAK1 | P23458 | 15/20 | 0.52 |
| ▸ | TYK2 | P29597 | 15/20 | 0.52 |
| ▸ | JAK3 | P52333 | 15/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436490 | 0.88 | JAK2 (0.55) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL19436506 | 0.81 | JAK2 (0.62) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL19436566 | 0.81 | JAK2 (0.62) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL25252813 | 0.81 | JAK2 (0.53) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL30586488 | 0.81 | JAK2 (0.53) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22121361 | 0.80 | KMT2A (0.54) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL19437515 | 0.79 | KMT2A (0.63) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL6023576 | 0.79 | KMT2A (0.56) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL30586467 | 0.78 | JAK2 (0.50) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL25303981 | 0.78 | JAK2 (0.50) | JAK2JAK1TYK2JAK3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| EP-3440072-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | ARGLU1, G3BP1, G3BP2 | JAK2 1117/4885JAK1 2274/4885TYK2 2851/4885 |
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | ARGLU1, G3BP1, G3BP2 | JAK2 1117/4885JAK1 2274/4885TYK2 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.